The current landscape of systemic therapy for recurrent glioblastoma: A systematic review of randomized-controlled trials

被引：13

作者：

Fazzari, Francesco G. T. ^{[1
]}

Rose, Foster ^{[1
]}

Pauls, Mehrnoosh ^{[2
]}

Guay, Evelyne ^{[1
]}

Ibrahim, Mohammed F. K. ^{[3
]}

Basulaiman, Bassam ^{[4
]}

Tu, Megan ^{[5
]}

Hutton, Brian ^{[6
,7
]}

Nicholas, Garth ^{[5
,8
]}

Ng, Terry L. ^{[5
,8
]}

机构：

[1] Univ Ottawa, Fac Med, 451 Smyth Rd 2044, Ottawa, ON K1H 8M5, Canada

[2] Univ British Columbia, BC Canc Ctr, 600 W 10th Ave, Vancouver, BC V5Z 4E6, Canada

[3] Northern Ontario Sch Med, Med Oncol, Div Clin Sci, 955 Oliver Rd, Thunder Bay, ON P7B 5E1, Canada

[4] King Fahad Med City, Comprehens Canc Ctr, Med Oncol Dept, Makkah Al Mukarramah Branch Rd, Riyadh 11564, Saudi Arabia

[5] Ottawa Hosp Res Inst, 1053 Carling Ave, Ottawa, ON K1Y 4E9, Canada

[6] Ottawa Hosp Res Inst, Clin Epidemiol Program, 1053 Carling Ave, Ottawa, ON K1Y 4E9, Canada

[7] Univ Ottawa, 1053 Carling Ave, Ottawa, ON K1Y 4E9, Canada

[8] Univ Ottawa, Dept Med, Div Med Oncol, 501 Smyth Rd, Ottawa, ON K1H 8L6, Canada

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2022年 / 169卷

关键词：

Chemotherapy; Antibody-drug conjugate; Anti-angiogenic; Immunotherapy; Recurrent glioblastoma; Systemic therapy; Systematic review; PHASE-II TRIAL; DOSE-INTENSE TEMOZOLOMIDE; BEVACIZUMAB PLUS LOMUSTINE; DOUBLE-BLIND; ADJUVANT TEMOZOLOMIDE; COMBINATION; INHIBITOR; BIOMARKER; EFFICACY; ADULTS;

D O I：

10.1016/j.critrevonc.2021.103540

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Aim: Conduct a systematic review of the effectiveness of systemic therapies for adult recurrent glioblastoma (rGBM). Methods: We electronically searched for randomized controlled trials from three major databases and four conferences from 2009-Dec 2020. Two independent reviewers conducted screening, data extraction, and quality assessment. Results: 48 randomized trials were identified. Outcome reporting was inconsistent: overall survival (OS) in 46 studies, progression free survival in 37 studies, 6-month PFS in 30 studies, objective response rate in 28 studies, and 6-month OS in 7 studies. Network meta-analysis was not feasible due to heterogeneity in outcome reporting and single-study linkages. Most studies compared lomustine (8 studies), bevacizumab (18), or temozolomide (8) with other treatments. The median OS across all studies ranged from 3 to 17.6 months. Conclusions: Based on level one evidence, there is no superior systemic regimen for rGBM. rGBM is a heterogeneous population with no single regimen demonstrating OS benefit.

引用

页数：20

共 98 条

[51] NRG/RTOG 1122: A phase 2, double-blinded, placebo-controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcoma [J].

Lee, Eudocia Q. ;

Zhang, Peixin ;

Wen, Patrick Y. ;

Gerstner, Elizabeth R. ;

Reardon, David A. ;

Aldape, Kenneth D. ;

deGroot, John F. ;

Pan, Edward ;

Raizer, Jeffrey J. ;

Kim, Lyndon J. ;

Chmura, Steven J. ;

Robins, H. Ian ;

Connelly, Jennifer M. ;

Battiste, James D. ;

Villano, John L. ;

Wagle, Naveed ;

Merrell, Ryan T. ;

Wendland, Merideth M. ;

Mehta, Minesh P. .

CANCER, 2020, 126 (12) :2821-2828

[52]

Liberati A, 2009, BMJ-BRIT MED J, V339, DOI [10.1016/j.ijsu.2010.02.007, 10.1371/journal.pmed.1000097, 10.1136/bmj.b2700, 10.1016/j.ijsu.2010.07.299, 10.1136/bmj.b2535, 10.1186/2046-4053-4-1, 10.1136/bmj.i4086]

[53] Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial [J].

Lombardi, Giuseppe ;

De Salvo, Gian Luca ;

Brandes, Alba Ariela ;

Eoli, Marica ;

Ruda, Roberta ;

Faedi, Marina ;

Lolli, Ivan ;

Pace, Andrea ;

Daniele, Bruno ;

Pasqualetti, Francesco ;

Rizzato, Simona ;

Bellu, Luisa ;

Pambuku, Ardi ;

Farina, Miriam ;

Magni, Giovanna ;

Indraccolo, Stefano ;

Gardiman, Marina Paola ;

Soffietti, Riccardo ;

Zagonel, Vittorina .

LANCET ONCOLOGY, 2019, 20 (01) :110-119

[54]

Lu Kan V, 2013, CNS Oncol, V2, P49

[55] A RANDOMIZED PHASE II TRIAL OF VANDETANIB (ZD6474) IN COMBINATION WITH CARBOPLATIN VERSUS CARBOPLATIN ALONE IN ADULTS WITH RECURRENT GLIOBLASTOMA [J].

McNeill, Katharine ;

Iwamoto, Fabio ;

Kreisl, Teri ;

Sul, Joohee ;

Shih, Joanna ;

Fine, Howard .

NEURO-ONCOLOGY, 2014, 16

[56] A randomized, double-blind, phase III trial of personalized peptide vaccination for recurrent glioblastoma [J].

Narita, Yoshitaka ;

Arakawa, Yoshiki ;

Yamasaki, Fumiyuki ;

Nishikawa, Ryo ;

Aoki, Tomokazu ;

Kanamori, Masayuki ;

Nagane, Motoo ;

Kumabe, Toshihiro ;

Hirose, Yuichi ;

Ichikawa, Tomotsugu ;

Kobayashi, Hiroyuki ;

Fujimaki, Takamitsu ;

Goto, Hisaharu ;

Takeshima, Hideo ;

Ueba, Tetsuya ;

Abe, Hiroshi ;

Tamiya, Takashi ;

Sonoda, Yukihiko ;

Natsume, Atsushi ;

Kakuma, Tatsuyuki ;

Sugita, Yasuo ;

Komatsu, Nobukazu ;

Yamada, Akira ;

Sasada, Tetsuro ;

Matsueda, Satoko ;

Shichijo, Shigeki ;

Itoh, Kyogo ;

Terasaki, Mizuhiko .

NEURO-ONCOLOGY, 2019, 21 (03) :348-359

[57] Phase 2 study of dose-intense temozolomide in recurrent glioblastoma [J].

Norden, Andrew D. ;

Lesser, Glenn J. ;

Drappatz, Jan ;

Ligon, Keith L. ;

Hammond, Samantha N. ;

Lee, Eudocia Q. ;

Reardon, David R. ;

Fadul, Camilo E. ;

Plotkin, Scott R. ;

Batchelor, Tracy T. ;

Zhu, Jay-Jiguang ;

Beroukhim, Rameen ;

Muzikansky, Alona ;

Doherty, Lisa ;

Lafrankie, Debra ;

Smith, Katrina ;

Tafoya, Vida ;

Lis, Rosina ;

Stack, Edward C. ;

Rosenfeld, Myrna R. ;

Wen, Patrick Y. .

NEURO-ONCOLOGY, 2013, 15 (07) :930-935

[58] Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143 [J].

Omuro, Antonio ;

Vlahovic, Gordana ;

Lim, Michael ;

Sahebjam, Solmaz ;

Baehring, Joachim ;

Cloughesy, Timothy ;

Voloschin, Alfredo ;

Ramkissoon, Shakti H. ;

Ligon, Keith L. ;

Latek, Robert ;

Zwirtes, Ricardo ;

Strauss, Lewis ;

Paliwal, Prashni ;

Harbison, Christopher T. ;

Reardon, David A. ;

Sampson, John H. .

NEURO-ONCOLOGY, 2018, 20 (05) :674-686

[59] Phase II Trial of Continuous Dose-Intense Temozolomide in Recurrent Malignant Glioma: RESCUE Study [J].

Perry, James R. ;

Belanger, Karl ;

Mason, Warren P. ;

Fulton, Dorcas ;

Kavan, Petr ;

Easaw, Jacob ;

Shields, Claude ;

Kirby, Sarah ;

Macdonald, David R. ;

Eisenstat, David D. ;

Thiessen, Brian ;

Forsyth, Peter ;

Pouliot, Jean-Francois .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (12) :2051-2057

[60]

Prados MD, 2003, NEURO-ONCOLOGY, V5, P96, DOI 10.1093/neuonc/5.2.96

← 1 2 3 4 5 6 7 8 9 10 →